Shares of immuno-oncology player Imugene Limited (ASX:IMU) rose as much as 6.6% to AU$0.485 during the morning trading session of 22 September 2021 following an encouraging update on HER-Vaxx immunotherapy. The shares continued to be in the green zone on 23 September, trading at A$0.475, up 1% (10:25 AM AEST). Clinical-stage immuno-oncology company Imugene is developing a range of new treatments with the support of a leading team of global cancer specialists having vast experience in developing new therapies to treat cancer. The treatments developed by Imugene seek to activate the immune system of patients for tumor identification and eradication.Imugene’s drug pipeline comprises multiple immunotherapy B-cell vaccine candidates and oncolytic virotherapy (CF33) targeted to treat several cancers in combination with standard of care drugs and developing immunotherapies.
Shares of immuno-oncology player Imugene Limited (ASX:IMU) rose...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.2¢ |
Change
-0.003(3.53%) |
Mkt cap ! $600.2M | |||
| Open | High | Low | Value | Volume |
| 8.5¢ | 8.6¢ | 8.2¢ | $1.246M | 14.84M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 446526 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.3¢ | 535664 | 2 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.2¢ |
Change
-0.003 ( 2.38 %) |
||||
| Open | High | Low | Volume | ||
| 8.6¢ | 8.6¢ | 8.2¢ | 4518456 | ||
| Last updated 15.57pm 03/05/2024 ? | |||||
| IMU (ASX) Chart |